trial · primary record
Dapagliflozin (DAPA)
COVID - 19
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 192 |
| Primary completion | 2029-06-30 |
| Primary endpoint | 6 month change in EQ-5D derived utility score. |
| Registry ID | NCT06907251 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:51.642Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06907251
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Dapagliflozin · approval
- Dapagliflozin · compound